David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Aptose Biosciences (APTO – Research Report), retaining the price target ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...